Provided are napthoquinone-type compounds which can be used to modulate
the aggregation of protein (e.g. tau) associated with neurodegenerative
disease (e.g. Alzheimer's disease). Structure-function characteristics
for oxidised and reduced napthoquinone-type compounds, such as
menadione-related compounds, are disclosed. The invention further
provides methods of treatment or prophylaxis of neurodegenerative
diseases and/or clinical dementias based on the compounds.
